Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | OGG1 | O15527 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1306220 | 1.00 | P2RX3 (0.42) | P2RX3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29488471 | 1.00 | P2RX3 (0.42) | P2RX3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29488459 | 0.95 | P2RX3 (0.44) | P2RX3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL1306538 | 0.95 | P2RX3 (0.44) | P2RX3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL1306531 | 0.95 | P2RX3 (0.44) | P2RX3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL1306726 | 0.92 | KDM4E (0.43) | P2RX3KDM4EPREPALDH1A1HPGD | |
| SCHEMBL1306723 | 0.92 | KDM4E (0.43) | P2RX3KDM4EPREPALDH1A1HPGD | |
| SCHEMBL1307230 | 0.91 | KDM4E (0.40) | P2RX3KDM4EPREPALDH1A1HPGD | |
| SCHEMBL1307233 | 0.91 | KDM4E (0.40) | P2RX3KDM4EPREPALDH1A1HPGD | |
| SCHEMBL29488460 | 0.89 | HDAC1 (0.40) | P2RX3HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220287993-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | CRYSTALGENOMICS, INC. (KR) | 2022-09-15 | — | — | US | claimed |
| WO-2022177054-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION | 크리스탈지노믹스(주) | 2022-08-25 | — | — | WO | claimed |
| EP-4026544-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | Crystalgenomics, Inc. (KR) | 2022-07-13 | — | — | EP | claimed |
| CN-114340672-A | Pharmaceutical composition comprising an HDAC inhibitor and an anti-PD 1 antibody or an anti-PD-L1 antibody | 晶体基因技术株式会社 | 2022-04-12 | — | — | CN | claimed |
| US-20210346321-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | CRYSTALGENOMICS, INC. (KR) | 2021-11-11 | — | — | US | claimed |
| EP-3875081-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | Crystalgenomics, Inc. (KR) | 2021-09-08 | — | — | EP | claimed |
| CN-112930177-A | Pharmaceutical composition containing alkylcarbamoylnaphthoxyoctenoylhydroxyamide phosphate, tartrate or combination thereof, and preparation method thereof | 晶体基因技术株式会社 | 2021-06-08 | — | — | CN | claimed |
| WO-2021045392-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | 크리스탈지노믹스(주) | 2021-03-11 | — | — | WO | claimed |
| CN-111867571-A | Pharmaceutical composition for preventing or treating fibrosis | 晶体基因技术株式会社 | 2020-10-30 | — | — | CN | claimed |
| US-20200283371-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2020-09-10 | — | — | US | claimed |
| EP-3640239-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2020-04-22 | — | — | EP | claimed |
| CN-110740989-A | Pharmaceutically acceptable salts of alkylcarbamoylnaphthoxyoctenoylhydroxyamides or derivatives thereof and process for preparing the same | 晶体基因技术株式会社 | 2020-01-31 | — | — | CN | claimed |
| WO-2019190214-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FIBROSIS | 크리스탈지노믹스(주) | 2019-10-03 | — | — | WO | claimed |
| EP-2913322-A2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | Korea Research Institute Of Chemical Technology (KR) | 2015-09-02 | — | — | EP | claimed |
| US-8053435-B2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-11-08 | — | — | US | claimed |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-18 | — | — | US | claimed |
| CN-101573327-A | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RES INST CHEM TECH (KR) | 2009-11-04 | — | — | CN | claimed |
| CN-112930177-B | Pharmaceutical compositions containing alkylcarbamoyl naphthoyl octenoyl hydroxyamide phosphate, tartrate or combinations thereof and methods of making the same | 晶体基因技术株式会社 | 2024-01-30 | — | — | CN | disclosed |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-18 | — | — | US | disclosed |
| CN-101573327-A | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RES INST CHEM TECH (KR) | 2009-11-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220287993-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | PDCD1, HDAC1, HDAC5 | P2RX3 4416/4885HDAC3 12/4885HDAC1 2/4885 |
| US-20210346321-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | AGPAT5, NOTUM, HADH | P2RX3 2046/4885HDAC3 1092/4885HDAC1 2152/4885 |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC3, HDAC11 | P2RX3 4630/4885HDAC3 2/4885HDAC1 1/4885 |
| US-20200283371-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | DOHH, CYP51A1, CYP46A1 | P2RX3 3692/4885HDAC3 1272/4885HDAC1 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.